Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ScopeVitamin D3 is a critical molecule for the properly controlled activity of the immune system. In myeloid‐derived cells, vitamin D3 induces the production of the antimicrobial and antitumor peptide cathelicidin. In this study, the mechanism of the entry of 25‐hydroxycholecalciferol (25(OH)D) in myeloid‐derived cells is explored.Methods and resultsHere, a novel regulatory pathway of vitamin D3 biology is described. Using a polyclonal antibody, two different chemical inhibitors, and a high‐density lipoprotein as a competing ligand, it is demonstrated here that the 25(OH)D signaling pathway in myeloid cells depends on scavenger receptor class B type I (SR‐B1). This effect is observed in the THP‐1 monocytic cell line and in human primary monocytes. SR‐B1 blockade abrogates the cellular uptake of 25(OH)D leading to a general shut down of the gene transcription program modulated by 25(OH)D. The results obtained at the transcriptional level are confirmed at the protein and functional level for CD14 in the THP‐1 cell line.ConclusionIn conclusion, SR‐B1 plays a critical role in vitamin D3 biology, paving the way for novel therapeutic interventions.

Original publication

DOI

10.1002/mnfr.201901213

Type

Journal article

Journal

Molecular Nutrition & Food Research

Publisher

Wiley

Publication Date

08/2020

Volume

64